全文获取类型
收费全文 | 255篇 |
免费 | 12篇 |
国内免费 | 7篇 |
专业分类
儿科学 | 1篇 |
基础医学 | 20篇 |
临床医学 | 125篇 |
内科学 | 40篇 |
特种医学 | 4篇 |
外科学 | 10篇 |
综合类 | 22篇 |
预防医学 | 30篇 |
眼科学 | 1篇 |
药学 | 10篇 |
中国医学 | 6篇 |
肿瘤学 | 5篇 |
出版年
2024年 | 2篇 |
2023年 | 15篇 |
2022年 | 25篇 |
2021年 | 58篇 |
2020年 | 22篇 |
2019年 | 6篇 |
2018年 | 2篇 |
2017年 | 1篇 |
2016年 | 5篇 |
2015年 | 2篇 |
2014年 | 14篇 |
2013年 | 10篇 |
2012年 | 21篇 |
2011年 | 13篇 |
2010年 | 8篇 |
2009年 | 4篇 |
2008年 | 5篇 |
2007年 | 5篇 |
2006年 | 2篇 |
2005年 | 5篇 |
2004年 | 3篇 |
2003年 | 5篇 |
2002年 | 4篇 |
2001年 | 6篇 |
2000年 | 4篇 |
1999年 | 3篇 |
1998年 | 2篇 |
1997年 | 7篇 |
1996年 | 5篇 |
1994年 | 2篇 |
1993年 | 3篇 |
1992年 | 2篇 |
1989年 | 1篇 |
1985年 | 1篇 |
1977年 | 1篇 |
排序方式: 共有274条查询结果,搜索用时 31 毫秒
1.
2.
《Transfusion and apheresis science》2022,61(4):103487
When the COVID-19 pandemic hit, blood transfusion services worldwide started collection of convalescent plasma as early as possible, as exemplified by the response in Norway. There were challenges related to donor selection, donor safety, testing for relevant antibodies and indications for and dosing of the convalescent plasma. As more knowledge became available, the product quality was more standardised. Multiple case reports, observational studies and some randomized studies were published during the pandemic, as well as laboratory studies reporting different approaches to antibody testing. The results were conflicting and the importance of convalescent plasma was disputed.Even though there has been strong international collaboration with involvement of many key organisations, we may better prepare for the next pandemic. An even stronger, more formalised collaboration between these organisations could provide more clear evidence of the importance of convalescent plasma, based on the principles of passive immunisation. 相似文献
3.
Pierre Tiberghien Xavier de Lamballerie Pascal Morel Pierre Gallian Karine Lacombe Yazdan Yazdanpanah 《Vox sanguinis》2020,115(6):488-494
Plasma provided by COVID-19 convalescent patients may provide therapeutic relief as the number of COVID-19 cases escalates steeply worldwide. Prior findings in various viral respiratory diseases including SARS-CoV-related pneumonia suggest that convalescent plasma can reduce mortality, although formal proof of efficacy is still lacking. By reducing viral spread early on, such an approach may possibly downplay subsequent immunopathology. Identifying, collecting, qualifying and preparing plasma from convalescent patients with adequate SARS-CoV-2-neutralizing Ab titres in an acute crisis setting may be challenging, although well within the remit of most blood establishments. Careful clinical evaluation should allow to quickly establish whether such passive immunotherapy, administered at early phases of the disease in patients at high risk of deleterious evolution, may reduce the frequency of patient deterioration, and thereby COVID-19 mortality. 相似文献
4.
《Vaccine》2021,39(45):6601-6613
AKS-452 is a biologically-engineered vaccine comprising an Fc fusion protein of the SARS-CoV-2 viral spike protein receptor binding domain antigen (Ag) and human IgG1 Fc (SP/RBD-Fc) in clinical development for the induction and augmentation of neutralizing IgG titers against SARS-CoV-2 viral infection to address the COVID-19 pandemic. The Fc moiety is designed to enhance immunogenicity by increasing uptake via Fc-receptors (FcγR) on Ag-presenting cells (APCs) and prolonging exposure due to neonatal Fc receptor (FcRn) recycling. AKS-452 induced approximately 20-fold greater neutralizing IgG titers in mice relative to those induced by SP/RBD without the Fc moiety and induced comparable long-term neutralizing titers with a single dose vs. two doses. To further enhance immunogenicity, AKS-452 was evaluated in formulations containing a panel of adjuvants in which the water-in-oil adjuvant, Montanide™ ISA 720, enhanced neutralizing IgG titers by approximately 7-fold after one and two doses in mice, including the neutralization of live SARS-CoV-2 virus infection of VERO-E6 cells. Furthermore, ISA 720-adjuvanted AKS-452 was immunogenic in rabbits and non-human primates (NHPs) and protected from infection and clinical symptoms with live SARS-CoV-2 virus in NHPs (USA-WA1/2020 viral strain) and the K18 human ACE2-trangenic (K18-huACE2-Tg) mouse (South African B.1.351 viral variant). These preclinical studies support the initiation of Phase I clinical studies with adjuvanted AKS-452 with the expectation that this room-temperature stable, Fc-fusion subunit vaccine can be rapidly and inexpensively manufactured to provide billions of doses per year especially in regions where the cold-chain is difficult to maintain. 相似文献
5.
目的 :研究综合康复治疗对恢复后期脑卒中患者运动功能及日常生活能力 (ADL)的影响。方法 :将 92例恢复后期脑卒中患者 ,随机分为康复组 5 0例 ,对照组 4 2例 ,两组一般治疗相同 ,康复组同时配合康复护理、运动疗法、作业疗法和电疗等综合康复治疗 8周。结果 :采用Fugl-Meyer运动功能评分 (FMA)和修订的Barthel指数 (MBI)评分 ,康复组各项指标评分明显优于对照组 (P <0 .0 5 )。结论 :综合康复治疗对于恢复后期脑卒中患者运动功能的恢复有明显效果 ,提高了ADL水平。 相似文献
6.
Sina Schwarzkopf Adalbert Krawczyk Dietmar Knop Hannes Klump Andreas Heinold Falko M. Heinemann Laura Thümmler Christian Temme Marianne Breyer Oliver Witzke Ulf Dittmer Veronika Lenz Peter A. Horn Monika Lindemann 《Emerging infectious diseases》2021,27(1):122
We investigated immune responses against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) among a group of convalescent, potential blood donors in Germany who had PCR-confirmed SARS-CoV-2 infection. Sixty days after onset of symptoms, 13/78 (17%) study participants had borderline or negative results to an ELISA detecting IgG against the S1 protein of SARS-CoV-2. We analyzed participants with PCR-confirmed infection who had strong antibody responses (ratio >3) as positive controls and participants without symptoms of SARS-CoV-2 infection and without household contact with infected patients as negative controls. Using interferon-γ ELISpot, we observed that 78% of PCR-positive volunteers with undetectable antibodies showed T cell immunity against SARS-CoV-2. We observed a similar frequency (80%) of T-cell immunity in convalescent donors with strong antibody responses but did not detect immunity in negative controls. We concluded that, in convalescent patients with undetectable SARS-CoV-2 IgG, immunity may be mediated through T cells. 相似文献
7.
8.
9.
Mari Terada Satoshi Kutsuna Tomiteru Togano Sho Saito Noriko Kinoshita Yumiko Shimanishi Tetsuya Suzuki Yusuke Miyazato Makoto Inada Takahito Nakamoto Hidetoshi Nomoto Satoshi Ide Mitsuhiro Sato Kenji Maeda Akihiro Matsunaga Masahiro Satake Keiji Matsubayashi Hirokazu Tsuno Makiko Kojima Madoka Kuramistu Kenta Tezuka Emi Ikebe Kazu Okuma Isao Hamaguchi Katsuyuki Shiratori Motohiko Sato Yuiko Kawakami Kumi Inaba Saori Igarashi Reina Yamauchi Mina Matsumura Keiko Ishimaru Bijuan Zhang Chika Kuge Maiko Ishihara Miho Gouda Keiko Tanaka Yukihito Ishizaka Norio Ohmagari 《Transfusion》2021,61(7):1998-2007
10.
Ana Paula H. Yokoyama Silvano Wendel Carolina Bonet-Bub Roberta M. Fachini Ana Paula F. Dametto Fernando Blumm Valeria F. Dutra Gabriela T. P. Candelaria Araci M. Sakashita Rafael Rahal Guaragna Machado Rita Fontão-Wendel Nelson Hamerschlak Ruth Achkar Murillo Santucci Cesar Assunção Patrícia Scuracchio Victor Nudelman Laerte Pastore João R. R. Pinho Mirian Dal Ben Roberto Kalil Filho Alexandre R. Marra Mariane T. Amano Esper G. Kallás Alfredo Salim Helito Carlos Roberto Ribeiro de Carvalho Danielle Bastos Araujo Edison Luiz Durigon Anamaria A. Camargo Luiz V. Rizzo Luiz F. L. Reis Jose M. Kutner 《Transfusion》2021,61(8):2295-2306